Q9611 (Q9611): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): For the fifth year, the applicant is engaged in industrial research and development in the field of nanotherapeutics with total biocompatibility. The aim of the project is to expand the portfolio of available methods and techniques so that the majority of key research activities can be carried out internally to eliminate the high risk of loss of know-how., Adding English summary) |
(Changed label, description and/or aliases in 1 language: remove_english_label) |
||
| label / en | label / en | ||
Revision as of 06:30, 22 October 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project in Czech Republic financed by DG Regio |
Statements
19,500,000.0 Czech koruna
0 references
39,000,000.0 Czech koruna
0 references
50 percent
0 references
4 November 2016
0 references
30 May 2018
0 references
1 June 2018
0 references
Therapharm, a.s.
0 references
50°10'4.12"N, 14°6'28.30"E
0 references
27309
0 references
Žadatel se pátým rokem zabývá průmyslovým výzkumem a vývojem v oblasti nanoterapeutik s totální biokompatibilitou. Cílem projektu je rozšířit portfolio dostupných metod a technik, tak aby bylo možné provádět většinu klíčových výzkumných aktivit interně a eliminovat tak vysoké riziko ztráty know-how. (Czech)
0 references
For the fifth year, the applicant is engaged in industrial research and development in the field of nanotherapeutics with total biocompatibility. The aim of the project is to expand the portfolio of available methods and techniques so that the majority of key research activities can be carried out internally to eliminate the high risk of loss of know-how. (English)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/15_002/0000129
0 references